基石药业-B(02616)：恒瑞医药启动一项抗CTLA-4单抗联合疗法一线治疗 ...
智通财经APP讯，基石药业-B(02616)发布公告，其战略合作伙伴江苏恒瑞医药股份有限公司(恒瑞医药)近日启动了CS1002/SHR-8068(抗CTLA-4单抗)联合阿得贝利单抗及贝伐珠单抗一线治疗晚期肝细胞癌(HCC)的III期临床研究。 该研究将通过评估客观缓解率(ORR)及总生存期(OS)，评价CS1002/SHR-8068联合阿得贝利单抗(抗PD-L1单抗)和贝伐珠单抗(试验组)对比信 ...
Shattuck Labs (STTK) was downgraded to a Hold Rating at H.C. Wainwright
Shattuck Labs (STTK – Research Report) received a Hold rating and price target from H.C. Wainwright analyst Joseph Pantginis today. The ...
News Medical12 小时
The role of FOXM1 and PD-L1 in malignant peripheral nerve sheath tumor resistance
A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, "Linking FOXM1 and PD-L1 to CDK4/6 ...
Armed robbery in Revesby17 小时
FOXM1, PD-L1 Linked to CDK4/6-MEK Resistance in Nerve Tumors
We suggest that future therapeutic strategies targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 represent ...
中時新聞網19 小时
长圣9月营收再创新高 估第四季业绩更好
长圣(6712)受惠于CDMO服务与全台19家医疗机构合作，自结9 月营收以9,002万元再创新高，连续9个月长红，累计前九月营收达5.89 亿元，年增率高达17.16％，再次刷新同期新高纪录，预期第四季营收将更好。总经理黄文良表 ...
Immune Checkpoint Inhibitors Market to hit USD 189.1 billion by 2032, says Global Market ...
Immune checkpoint inhibitors industry is projected to witness a CAGR of 16.7% during the period 2024-2032. This growth can be ...
EurekAlert!1 天
FOXM1 and PD-L1 in CDK4/6-MEK resistance in nerve tumors
A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Linking FOXM1 and PD-L1 to CDK4/6 ...
Cure Today1 天
Long-Term Study Data Support Keytruda as Standard of Care for Advanced Melanoma
They could have received up to one prior systemic treatment as long as it was not an anti–CTLA-4, PD-1, PD-L1, or PD-L1 agent ...
中時新聞網1 天
中国附医圣安强强联手 获国际期刊肯定
中国附医30日宣布，由院长周德阳团队携手圣安开发奈米三特异性T细胞衔接抗体「Nb-TriTE」抗癌药物（SOA101），成功完成临床前研究，该研究成果发表于国际知名期刊《Advanced Science》并获得高分肯定，近期也向美国F ...
康方生物(09926)：国家药监局批准开坦尼(卡度尼利，PD-1/CTLA-4)联合 ...
智通财经APP讯，康方生物(09926)发布公告，中华人民共和国国家药品监督管理局(NMPA)官网系统显示，公司自主研发的全球首创肿瘤免疫治疗药物双特异性抗体开坦尼(卡度尼利，PD-1/CTLA-4)的一项新适应症上市申请(sNDA)的状态更新为“制 ...
Improving next-generation cancer treatments with cryoimmunotherapy
Northwestern Medicine scientists have developed a more effective method of delivering a cutting-edge cancer treatment, ...
Merus启动头颈癌治疗的3期临床试验
荷兰乌特勒支 - 临床阶段肿瘤公司Merus N.V. (NASDAQ:MRUS)宣布启动一项3期临床试验，研究新型癌症治疗药物petosemtamab与pembrolizumab联合用于复发或转移性头颈部鳞状细胞癌(r/m HNSCC)患者的治疗。LiGeR-HN1试验已完成首例患者给药，该试验将比较这种联合疗法与单独使用pembrolizumab作为一线治疗的疗效和安全性。 Petosemta ...